EC
IMVT icon

EntryPoint Capital’s Immunovant IMVT Stock Holding History

EntryPoint Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,738
Closed -$249K – 841
2024
Q3 		$249K Buy
8,738
+8,268
+1,759% +$244K 0.14% 340
2024
Q2 		$12.4K Sell
470
-2,442
-84% -$69.5K 0.02% 746
2024
Q1 		$94.1K Buy
2,912
+2,163
+289% +$78.9K 0.08% 464
2023
Q4 		$31.6K Buy
+749
New +$27.6K 0.03% 905

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EntryPoint Capital's IMVT Position: Q4 2024 in Review

EntryPoint Capital sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 8,738 shares — an estimated $249K sold.

EntryPoint Capital first reported a position in IMVT in Q4 2023 and held it in 4 quarters. The position peaked at $249K in Q3 2024. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • EntryPoint Capital reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 8,738 Immunovant shares in Q4 2024, an estimated $249K.
  • EntryPoint Capital first reported a position in Immunovant in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Immunovant position peaked at $249K in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.